Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA)

被引:0
|
作者
Giovanni DiPaolo
Cecilia Jimenez-Moreno
Nikoletta Nikolenko
Antonio Atalaia
Darren G. Monckton
Michela Guglieri
Hanns Lochmüller
机构
[1] Keel University School of Medicine,John Walton Muscular Dystrophy Research Centre
[2] Newcastle University,Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences
[3] University of Glasgow,undefined
[4] Newcastle Upon Tyne Hospitals NHS Foundation Trust,undefined
来源
Journal of Neurology | 2017年 / 264卷
关键词
Myotonic dystrophy; Falls; DM1; Balance;
D O I
暂无
中图分类号
学科分类号
摘要
Myotonic dystrophy type 1 (DM1) is not characterised by ataxia per se; however, DM1 and ataxia patients show similar disturbances in movement coordination often experiencing walking and balance difficulties, although caused by different underlying pathologies. This study aims to investigate the use of a scale previously described for the assessment and rating of ataxia (SARA) with the hypothesis that it could have utility in DM1 patients as a measure of disease severity and risk of falling. Data from 54 DM1 patients were pulled from the PHENO-DM1 natural history study for analysis. Mean SARA score in the DM1 population was 5.45 relative to the maximum score of eight. A flooring effect (score 0) was observed in mild cases within the sample. Inter-rater and test–retest reliability was high with intraclass coefficients (ICC) of 0.983 and 1.00, respectively. Internal consistency was acceptable as indicated by a Cronbach’s alpha of 0.761. Component analysis revealed two principle components. SARA correlated with: (1) all measures of muscle function tested, including quantitative muscle testing of ankle dorsiflexion (r = −0.584*), the 6 min walk test (r = −0.739*), 10 m walk test (r = 0.741*), and the nine hole peg test (r = 0.602*) and (2) measures of disease severity/burden, such as MIRS (r = 0.718*), MDHI (r = 0.483*), and DM1-Activ (r = −0.749*) (*p < 0.001). The SARA score was predicted by an interaction between modal CTG repeat length and age at sampling (r = 0.678, p = 0.003). A score of eight or above predicted the use of a walking aid with a sensitivity of 100% and a specificity of 85.7%. We suggest that further research is warranted to ascertain whether SARA or components of SARA are useful outcome measures for clinical trials in DM1. As a tool, it can be used for gathering information about disease severity/burden and helping to identify patients in need of a walking aid, and can potentially be applied in both research and healthcare settings.
引用
收藏
页码:701 / 708
页数:7
相关论文
共 50 条
  • [41] Rare Disease: Cardiac Risk Assessment With MRI in Patients With Myotonic Dystrophy Type 1
    Ali, Marco
    Monti, Caterina Beatrice
    Melazzini, Luca
    Cardani, Rosanna
    Fossati, Barbara
    Cavalli, Michele
    Chow, Kelvin
    Secchi, Francesco
    Meola, Giovanni
    Sardanelli, Francesco
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [42] Assessment of body composition, metabolism, and pulmonary function in patients with myotonic dystrophy type 1
    Kikuchi, Kazuto
    Satake, Masahiro
    Furukawa, Yutaka
    Terui, Yoshino
    MEDICINE, 2022, 101 (36) : E30412
  • [43] Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study
    Petri, Helle
    Ahtarovski, Kiril Aleksov
    Vejlstrup, Niels
    Vissing, John
    Witting, Nanna
    Kober, Lars
    Bundgaard, Henning
    JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2014, 16
  • [44] Insufficiency of electrocardiogram alone in predicting infrahisian abnormalities in patients with type 1 myotonic dystrophy
    Simeon, Edouard
    Patier-Dussauge, Aurelie
    Bernard-Brunet, Anne
    Clementy, Nicolas
    Gouraud, Jean-Baptiste
    Guyomarch, Beatrice
    Magot, Armelle
    Probst, Vincent
    Babuty, Dominique
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (03) : 625 - 627
  • [45] Quality of life and subjective symptom impact in Japanese patients with myotonic dystrophy type 1
    Haruo Fujino
    Toshio Saito
    Masanori P. Takahashi
    Hiroto Takada
    Takahiro Nakayama
    Osamu Imura
    Tsuyoshi Matsumura
    BMC Neurology, 22
  • [46] Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study
    Helle Petri
    Kiril Aleksov Ahtarovski
    Niels Vejlstrup
    John Vissing
    Nanna Witting
    Lars Køber
    Henning Bundgaard
    Journal of Cardiovascular Magnetic Resonance, 16
  • [47] MRI of trunk muscles and motor and respiratory function in patients with myotonic dystrophy type 1
    Solbakken, Gro
    Bjornara, Bard
    Kirkhus, Eva
    Bac Nguyen
    Hansen, Gunnar
    Frich, Jan C.
    Orstavik, Kristin
    BMC NEUROLOGY, 2019, 19
  • [48] LOWER LIMB MUSCLE STRENGTH IMPAIRMENT IN LATE-ONSET AND ADULT MYOTONIC DYSTROPHY TYPE 1 PHENOTYPES
    Petitclerc, Emilie
    Hebert, Luc J.
    Mathieu, Jean
    Desrosiers, Johanne
    Gagnon, Cynthia
    MUSCLE & NERVE, 2017, 56 (01) : 57 - 63
  • [49] Ventricular stimulation in patients with myotonic dystrophy type 1 may not predict future ventricular arrhythmias
    Cerbin, Lukasz
    Sandhu, Amneet
    Rosenberg, Michael
    Barrett, Christopher
    Sabzwari, Rafay
    Garg, Lohit
    Tumolo, Alexis
    Tzou, Wendy
    Varosy, Paul
    Von Alvensleben, Johannes
    Zipse, Matthew
    Aleong, Ryan
    HEART RHYTHM O2, 2024, 5 (10): : 698 - 704
  • [50] The Role of the Atrial Electromechanical Delay in Predicting Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients
    Russo, Vincenzo
    Rago, Anna
    Ciardiello, Carmine
    Russo, Maria Giovanna
    Calabro, Paolo
    Politano, Luisa
    Nigro, Gerardo
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2016, 27 (01) : 65 - 72